Zomedica stock’s decline can be linked to some investors getting frustrated with delays in ramping up Truforma platform sales. Zomedica initially signed a distribution partner to sell Truforma on its behalf but later changed its mind. Instead, it will build an internal direct sales team for the product.
What happened to zomedica stock?
Apr 16, 2021 · CEO Robert Cohen said the move was precipitated by "changes at our current distributor that we believe have impacted its ability to market our products effectively." Those words likely startled...
What does zomedica do?
Mar 23, 2021 · Zomedica's recent stock price movements appear to be a classic "buy the rumor, sell the news" event. Traders on Reddit and other social media sites have hyped Zomedica's growth prospects in recent ...
Why did Zom stock drop after launching truforma?
Feb 09, 2021 · Yesterday, Zomedica moved to cash in on the incredible rally in its stock price by selling nearly 13.2 million of its shares to investors at a price of $1.90 per share. Zomedica surrendered some ...
What happened to Zom stock in 2021?
Apr 06, 2021 · Why Zomedica stock is dropping Over the last month, investors have exited speculative stocks like ZOM. Also, given the rising bond yields, there has been a sell-off in companies whose cash flows...
Is Zomedica Pharmaceuticals a good stock to buy?
In the final analysis, ZOM stock is highly risky and best suited for speculative traders. Yet it's possible that retail traders will bid the stock up in 2022. And if they abandon Zomedica, it would be a dog-gone shame.Jan 7, 2022
What is wrong with Zomedica stock?
Zomedica's shares have plunged more than 80% after skyrocketing earlier this year. The company has experienced problems with a distribution partner being acquired and a development partner's delays. Zomedica could rebound once new assays for its Truforma instrument are available.Aug 19, 2021
Is Zomedica expected to rise?
The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. The median estimate represents a +292.16% increase from the last price of 0.31.
Why did Zomedica stock go up?
The big jump came after the veterinary health company provided a sneak peek at its 2021 fourth-quarter and full-year revenue following the market close on Friday. Zomedica reported total revenue in the fourth quarter and full-year 2021 of $4.1 million.Feb 28, 2022
Will Zomedica go up tomorrow?
Tomorrow's movement Prediction of Zomedica Pharmaceuticals Corp ZOM as on 08 Apr 2022 appears strongly Bullish. This stock started moving upwards as soon as it opened....Munafa value: 55 as on 08 Fri Apr 2022.Upside target0.33Upside target0.31Downside target0.3Downside target0.291 more row
Will Zomedica stock go up in 2022?
Target values for the price of one Zomedica share for Nov 2022. The weighted average target price per Zomedica share in Nov 2022 is: 0.29. In Nov, the positive dynamics for Momo shares will prevail with possible monthly volatility of 17.333% volatility is expected.Apr 11, 2022
What is Zomedica target price?
Stock Price TargetsHigh$1.20Median$1.20Low$1.20Average$1.20Current Price$0.35
Investors who bought the rumor now appear to be selling the news
Joe honed his investing skills as an analyst for Stock Advisor. He battle-tested his investment philosophy and strategies as portfolio manager of Tier 1, a market-crushing Motley Fool real-money portfolio that delivered 24.58% annualized returns.
What happened
Shares of Zomedica ( NYSEMKT:ZOM) fell 10.5% Tuesday, furthering the decline in the veterinary health company's stock price over the past week.
So what
Zomedica's shares have shed roughly 28% of their value since the company announced the first sale of its Truforma system on March 16. The diagnostic platform for dogs and cats is Zomedica's first commercial product.
Now what
Zomedica's recent stock price movements appear to be a classic "buy the rumor, sell the news" event. Traders on Reddit and other social media sites have hyped Zomedica's growth prospects in recent weeks, which has helped to propel the huge surge in its stock price.
The veterinary health specialist is selling more shares than investors expected
Joe honed his investing skills as an analyst for Stock Advisor. He battle-tested his investment philosophy and strategies as portfolio manager of Tier 1, a market-crushing Motley Fool real-money portfolio that delivered 24.58% annualized returns.
What happened
Shares of Zomedica ( NYSEMKT:ZOM) fell 14% on Tuesday after the pet health company disclosed that it was increasing the size of its stock offering by nearly sevenfold.
So what
On Nov. 13, Zomedica announced commercialization plans for its Truforma diagnostic platform for cats and dogs. Its stock subsequently went on to soar a stunning 2,750%.
Now what
It's rare for a company to increase its share offering so significantly, especially at such a late hour. It's thus somewhat surprising that Zomedica's stock price didn't decline even more on Tuesday.
How much is the companion animal diagnostics market?
The market for companion animal diagnostics was $1.7 billion in 2019, which ZOM expects to rise to $2.8 billion by 2024 citing data from MarketsandMarkets. Even after the fall, ZOM stock has a market capitalization of $1.3 billion. This is more than double the forecasted 2025 market opportunity for companion animal diagnostics.
Is Zomedica a good company?
Zomedica is a niche company and is a good way to play the animal diagnostic market. According to Zomedica, nearly two-thirds of U.S. households have at least one pet and most of the households with a pet dog visit a veterinarian annually.
Why is ZOM stock dropping?
Zomedica shares have fallen more than 30 percent in the past month and 80 percent from their Feb. 2021 peak. Zomedica stock’s decline can be linked to some investors getting frustrated with delays in ramping up Truforma platform sales.
Will Zomedica (ZOM) stock go back up?
In its latest corporate update, Zomedica implied that setting up the internal sales force for Truforma is progressing well and sales should begin to materialize soon. It said it expects to close the year with 15 sales representatives, and other industry professionals will support the team.
Zomedica's (ZOM) stock price forecast
Wall Street analysts' average price target of $1.20 for ZOM suggests the stock could rise more than 90 percent in the next 12 months.
Zomedica's FDA approval
Zomedica’s Truforma platform, which produces diagnostic results on the spot, went on sale in Mar. 2021. Its sales are still minimal (just over $14,000 in the first quarter) as the company works on the internal marketing team.
Should you buy or sell Zomedica (ZOM) stock?
Penny stocks require extra caution, and Zomedica stock is no exception. But ZOM looks like it could pay off well for patient investors—at about 80 percent below its peak, it could be a good deal.
Why is Zomedica failing?
A significant reason why Zomedica may be failing to gain traction is that Truforma treats a small slice of the overall pet care market. If you’ve ever had to wait to receive lab results for your furry family members Ior yourself for that matter), then you understand the benefit of a point-of-care test.
Is Zomedica capitalized?
Also, although Zomedica is well capitalized at the moment, there is some concern that it may attempt to go on an acquisition spree. As Will Ashworth points out, the company’s new Vice President of Business Development has a history of completing acquisitions.
Does Zomedica have a moat?
However, the test is only applicable to specific conditions. And Zomedica does not have a moat in that space. One of the company’s strongest competitors is IDEXX Laboratories (NASDAQ: IDXX ). This doesn’t mean that there isn’t a market for Truforma.